-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F1GJ/vY9+mZfN310/j9biR0vCTftWbJh2NGGe0/Zbme3Q2ji6DsPMyJqZqsMiHz3 qwvRgMWdmqdWphuMMAQPrw== 0001140361-07-016823.txt : 20070817 0001140361-07-016823.hdr.sgml : 20070817 20070817174947 ACCESSION NUMBER: 0001140361-07-016823 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070815 FILED AS OF DATE: 20070817 DATE AS OF CHANGE: 20070817 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 5105741400 MAIL ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Iwanicki David CENTRAL INDEX KEY: 0001322481 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 071066117 BUSINESS ADDRESS: BUSINESS PHONE: 510-574-1400 MAIL ADDRESS: STREET 1: 34801 CAMPUS DRIVE CITY: FREMONT STATE: CA ZIP: 94555 4 1 doc1.xml FORM 4 X0202 4 2007-08-15 0 0000882104 PDL BIOPHARMA, INC. PDLI 0001322481 Iwanicki David C/O PDL BIOPHARMA, INC. 34801 CAMPUS DRIVE FREMONT CA 94555 0 1 0 0 VP, Sales & Sales Operations Employee Stock Option (Right to Buy) 22.10 2007-08-15 4 A 0 22500 0 A 2014-08-15 Common Stock 22500 22500 D This option vests with respect to 1/48 of the shares per month over four years after August 15, 2007, the date of grant. Only vested options are exercisable. /s/ Francis Sarena by Francis Sarena, Attorney- in- Fact for David Iwanicki 2007-08-17 -----END PRIVACY-ENHANCED MESSAGE-----